BioSpace News Archive

Denali Therapeutics Inc. today announced that its partner Sanofi has commenced dosing in a Phase 2 study of SAR443820 (DNL788) in individuals with multiple sclerosis. SAR443820 is a central nervous system (CNS)-penetrant investigational small molecule inhibitor of RIPK1.

Capricor to Host Webinar in Conjunction with Parent Project Muscular Dystrophy (PPMD) Today at 1:00 p.m. ET.

IceCure Medical Ltd today announced that on January 13-14, 2023, the Company participated in the American Society of Breast Surgeons (“ASBrS”) Breast Fellows Ultrasound Course in Cincinnati, Ohio.

Inhibikase Therapeutics, Inc. today announced the U.S. Food and Drug Administration (“FDA” or “Agency”) has lifted the full Clinical Hold on IkT-148009 in Parkinson’s disease (PD).

Nascent Biotech, Inc. announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab as a treatment for Brain Cancer.

Electromedical Technologies, Inc. (OTC-QB: EMED) (“Electromedical” or the “Company”) and Sika Health, an HSA/FSA payment facilitator for eCommerce merchants, are pleased to announce a partnership enabling the direct acceptance of HSA/FSA payments on the Electromedical eCommerce website (electromedtech.com).

TOMI Environmental Solutions, Inc.® announces that TOMI will present its SteraMist brand of products at three upcoming International Society for Pharmaceutical Engineering (ISPE) Conferences in the first quarter of 2023.

Innate Pharma SA announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the previously announced expansion of its collaboration with Sanofi.

Pivotal study data published in The New England Journal of Medicine continues to highlight the efficacy, safety, and pharmacokinetic profile of efanesoctocog alfa, an investigational treatment for hemophilia A.